No FDA-Approved Medications for Gambling Disorder
There are currently no FDA-approved medications for the treatment of gambling disorder. This represents a significant gap in the therapeutic armamentarium for this condition, which affects approximately 0.5% of the adult population and is associated with substantial functional impairment, suicidality, and criminality 1.
Current State of Pharmacotherapy
While no medications have formal FDA approval for gambling disorder, the evidence base suggests some off-label options may be considered:
Opioid Antagonists (Strongest Evidence)
Naltrexone and nalmefene show the most promise among pharmacological agents, with several double-blind, placebo-controlled studies demonstrating efficacy in reducing gambling urges and behavior 2. Of 24 randomized controlled trials examining various medications (n=1,547 patients), only 4 of 7 studies on opioid antagonists showed significantly better results than placebo 3. These agents may work by modulating reward pathways in the striatum that are implicated in gambling disorder 2.
Other Agents with Limited Evidence
Multiple other drug classes have been investigated with inconsistent or negative results 3, 4, 5:
- Antidepressants (fluvoxamine, paroxetine, sertraline, citalopram, escitalopram)
- Mood stabilizers (lithium, valproate)
- Anticonvulsants (topiramate)
- Antipsychotics (olanzapine)
- Glutamate modulators (N-acetylcysteine, memantine)
The evidence for these agents is conflicting and inconclusive, with small to moderate effect sizes in some post-hoc analyses but significant methodological limitations 5.
Clinical Approach
First-Line Treatment: Psychotherapy
Cognitive behavioral therapy (CBT) and motivational interviewing (MI) should be the primary treatment approach, as these have the strongest evidence base over the past 20 years 2. CBT has been effective in various formats including individual therapy, group therapy, imaginal desensitization, and brief bibliotherapy interventions.
When to Consider Off-Label Pharmacotherapy
Reserve opioid antagonists (naltrexone or nalmefene) for patients who fail to respond to psychotherapeutic interventions 3. This recommendation is based on:
- The lack of FDA approval for any medication
- Limited and inconsistent evidence for most agents
- The relatively stronger (though still modest) evidence for opioid antagonists
- The need to avoid polypharmacy without clear benefit
Comorbidity-Guided Selection
When pharmacotherapy is considered, let comorbid psychiatric disorders guide medication selection 5. Gambling disorder frequently co-occurs with depression, substance use disorders, ADHD, and other conditions 6, 1. Treating these comorbidities may indirectly improve gambling symptoms.
Critical Limitations and Caveats
The current evidence base has substantial weaknesses 2, 5:
- No data on treatment sequencing or optimal duration
- Unknown predictors of treatment response
- Lack of personalized medicine approaches
- Small sample sizes and inconsistent study designs
- Contradictory results across trials
- Insufficient understanding of neurobehavioral mechanisms
The 2022 Lancet Psychiatry guidelines explicitly call for urgent randomized controlled trials on both psychological interventions and pharmacotherapy to address these knowledge gaps 2.
Bottom Line for Clinical Practice
Given the absence of FDA-approved medications and the limited evidence base, prioritize evidence-based psychotherapy (CBT, MI) as first-line treatment. Consider off-label naltrexone or nalmefene only in psychotherapy non-responders, recognizing this is based on modest evidence from placebo-controlled trials rather than regulatory approval. All other pharmacological agents lack sufficient evidence to recommend for routine use in gambling disorder.